Table 1.
Size and Distribution of the PCI Population in Spain Over Three Years
| Year 1 | Year 2 | Year 3 | References | |
|---|---|---|---|---|
| Population size | ||||
| Total PCI, n | 74,217 | 75,978 | 77,768 | 22,23 |
| STEMI/Primary PCI population, % | 100% | 100% | 100% | KOL |
| Primary/Total PCI, % | 25% | 25% | 25% | 23,25 |
| Total PCI population in whom oral P2Y12 inhibitors are not feasible or desirable/Total PCI population, % | 1.02% | 3.00% | 5.37% | 13,26,27 |
| Total population in whom oral P2Y12 inhibitors are not feasible or desirable, n | 760 | 2,280 | 4,180 | |
| Three-years total population in whom oral P2Y12 inhibitors are not feasible or desirable, n | 7,220 | |||
| Patients in whom antiplatelet treatment with oral P2Y12 inhibitors would be needed, n | 607 | 1,822 | 3,340 | |
| Three-years population in whom antiplatelet treatment with oral P2Y12 inhibitors would be needed, n | 5,769 | |||
| Population diagnosis | ||||
| ST-elevation myocardial infarction (STEMI) | 30% | 30% | 30% | 11,23 |
| Non-ST-elevation myocardial infarction (NSTEMI) | 40% | 40% | 40% | |
| Stable coronary artery disease (SCAD) | 22% | 22% | 22% | |
| Others | 8% | 8% | 8% | |
Abbreviations: KOL, key opinion leader; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.